The FDA says that food companies will have until Jan. 15, 2027 to stop using the dye. Drugmakers will have an extra year, ...

The decision by Trump’s team to tap Heather Flick as HHS chief of staff signals an effort to keep closer watch on the ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

Johnson & Johnson announced it has initiated the submission of an original New Drug Application with the U.S. FDA for TAR-200 for the ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

RARITAN, N.J. - Johnson & Johnson (NYSE:JNJ) has begun the process for U.S. Food and Drug Administration (FDA) approval of TAR-200, a new treatment option for high-risk non-muscle-invasive bladder ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

Bryan Johnson, a tech entrepreneur, has stopped using rapamycin, a drug not approved for anti-aging by the FDA, following ...

Johnson & Johnson CEO highlights Lecrazas potential to transform lung cancer treatment Johnson & Johnsons leader underscores ...